nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—CYP3A5—Beclomethasone—psoriasis	0.0733	0.111	CbGbCtD
Iloperidone—CYP1A2—Clobetasol propionate—psoriasis	0.0719	0.109	CbGbCtD
Iloperidone—CYP1A2—Methoxsalen—psoriasis	0.0378	0.0572	CbGbCtD
Iloperidone—CYP2D6—Hydroxyurea—psoriasis	0.034	0.0515	CbGbCtD
Iloperidone—CYP3A7—Hydrocortisone—psoriasis	0.0312	0.0472	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0312	0.0472	CbGbCtD
Iloperidone—CYP3A7—Cyclosporine—psoriasis	0.0295	0.0446	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0295	0.0446	CbGbCtD
Iloperidone—CYP3A5—Mycophenolate mofetil—psoriasis	0.0292	0.0441	CbGbCtD
Iloperidone—CYP3A4—Calcitriol—psoriasis	0.0255	0.0385	CbGbCtD
Iloperidone—CYP3A5—Hydrocortisone—psoriasis	0.0234	0.0354	CbGbCtD
Iloperidone—CYP3A5—Cyclosporine—psoriasis	0.0221	0.0334	CbGbCtD
Iloperidone—CYP2D6—Cholecalciferol—psoriasis	0.0206	0.0312	CbGbCtD
Iloperidone—CYP3A4—Methoxsalen—psoriasis	0.0198	0.0299	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0194	0.0293	CbGbCtD
Iloperidone—CYP3A7—Dexamethasone—psoriasis	0.0194	0.0293	CbGbCtD
Iloperidone—CYP2E1—Dexamethasone—psoriasis	0.0187	0.0283	CbGbCtD
Iloperidone—CYP3A5—Dexamethasone—psoriasis	0.0146	0.022	CbGbCtD
Iloperidone—CYP2D6—Cyclosporine—psoriasis	0.0136	0.0205	CbGbCtD
Iloperidone—CYP3A4—Cholecalciferol—psoriasis	0.0131	0.0198	CbGbCtD
Iloperidone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0114	0.0172	CbGbCtD
Iloperidone—CYP3A4—Triamcinolone—psoriasis	0.0114	0.0172	CbGbCtD
Iloperidone—CYP3A4—Betamethasone—psoriasis	0.00976	0.0148	CbGbCtD
Iloperidone—CYP3A4—Prednisolone—psoriasis	0.00963	0.0146	CbGbCtD
Iloperidone—CYP3A4—Hydrocortisone—psoriasis	0.00913	0.0138	CbGbCtD
Iloperidone—CYP3A4—Prednisone—psoriasis	0.00909	0.0137	CbGbCtD
Iloperidone—CYP2D6—Dexamethasone—psoriasis	0.00892	0.0135	CbGbCtD
Iloperidone—CYP3A4—Cyclosporine—psoriasis	0.00862	0.013	CbGbCtD
Iloperidone—CYP3A4—Dexamethasone—psoriasis	0.00567	0.00858	CbGbCtD
Iloperidone—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.00101	1	CbGdCrCtD
Iloperidone—Conjunctivitis—Betamethasone—psoriasis	0.000235	0.000803	CcSEcCtD
Iloperidone—Hypotension—Mycophenolic acid—psoriasis	0.000234	0.000801	CcSEcCtD
Iloperidone—Vision blurred—Cyclosporine—psoriasis	0.000234	0.000801	CcSEcCtD
Iloperidone—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000233	0.000797	CcSEcCtD
Iloperidone—Tremor—Cyclosporine—psoriasis	0.000233	0.000796	CcSEcCtD
Iloperidone—Lethargy—Methotrexate—psoriasis	0.000233	0.000796	CcSEcCtD
Iloperidone—Arrhythmia—Prednisolone—psoriasis	0.000232	0.000794	CcSEcCtD
Iloperidone—Anaemia—Cyclosporine—psoriasis	0.00023	0.000785	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000228	0.000781	CcSEcCtD
Iloperidone—Agitation—Cyclosporine—psoriasis	0.000228	0.000781	CcSEcCtD
Iloperidone—Tremor—Mycophenolate mofetil—psoriasis	0.000227	0.000777	CcSEcCtD
Iloperidone—Arrhythmia—Hydrocortisone—psoriasis	0.000226	0.000775	CcSEcCtD
Iloperidone—Nausea—Acitretin—psoriasis	0.000226	0.000774	CcSEcCtD
Iloperidone—Nausea—Fluocinolone Acetonide—psoriasis	0.000226	0.000772	CcSEcCtD
Iloperidone—Paraesthesia—Mycophenolic acid—psoriasis	0.000225	0.00077	CcSEcCtD
Iloperidone—Anaemia—Mycophenolate mofetil—psoriasis	0.000224	0.000766	CcSEcCtD
Iloperidone—Dyspnoea—Mycophenolic acid—psoriasis	0.000223	0.000764	CcSEcCtD
Iloperidone—Vertigo—Cyclosporine—psoriasis	0.000223	0.000763	CcSEcCtD
Iloperidone—Somnolence—Mycophenolic acid—psoriasis	0.000223	0.000762	CcSEcCtD
Iloperidone—Agitation—Mycophenolate mofetil—psoriasis	0.000223	0.000762	CcSEcCtD
Iloperidone—Leukopenia—Cyclosporine—psoriasis	0.000222	0.000761	CcSEcCtD
Iloperidone—Mental disorder—Hydrocortisone—psoriasis	0.000222	0.00076	CcSEcCtD
Iloperidone—Malnutrition—Hydrocortisone—psoriasis	0.000221	0.000755	CcSEcCtD
Iloperidone—Vertigo—Mycophenolate mofetil—psoriasis	0.000218	0.000745	CcSEcCtD
Iloperidone—Erectile dysfunction—Prednisone—psoriasis	0.000217	0.000743	CcSEcCtD
Iloperidone—Leukopenia—Mycophenolate mofetil—psoriasis	0.000217	0.000742	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000216	0.00074	CcSEcCtD
Iloperidone—Fatigue—Mycophenolic acid—psoriasis	0.000216	0.000739	CcSEcCtD
Iloperidone—Mood swings—Methotrexate—psoriasis	0.000216	0.000739	CcSEcCtD
Iloperidone—Asthenia—Hydroxyurea—psoriasis	0.000215	0.000734	CcSEcCtD
Iloperidone—Weight increased—Prednisone—psoriasis	0.000214	0.000734	CcSEcCtD
Iloperidone—Palpitations—Mycophenolate mofetil—psoriasis	0.000214	0.000733	CcSEcCtD
Iloperidone—Arrhythmia—Triamcinolone—psoriasis	0.000213	0.00073	CcSEcCtD
Iloperidone—Weight decreased—Prednisone—psoriasis	0.000213	0.00073	CcSEcCtD
Iloperidone—Vision blurred—Prednisolone—psoriasis	0.000213	0.000729	CcSEcCtD
Iloperidone—Arthralgia—Cyclosporine—psoriasis	0.000211	0.000723	CcSEcCtD
Iloperidone—Myalgia—Cyclosporine—psoriasis	0.000211	0.000723	CcSEcCtD
Iloperidone—Dry mouth—Cyclosporine—psoriasis	0.000207	0.000708	CcSEcCtD
Iloperidone—Feeling abnormal—Mycophenolic acid—psoriasis	0.000206	0.000706	CcSEcCtD
Iloperidone—Myalgia—Mycophenolate mofetil—psoriasis	0.000206	0.000706	CcSEcCtD
Iloperidone—Arthralgia—Mycophenolate mofetil—psoriasis	0.000206	0.000706	CcSEcCtD
Iloperidone—Breast disorder—Methotrexate—psoriasis	0.000206	0.000705	CcSEcCtD
Iloperidone—Diarrhoea—Hydroxyurea—psoriasis	0.000205	0.0007	CcSEcCtD
Iloperidone—Confusional state—Cyclosporine—psoriasis	0.000204	0.000699	CcSEcCtD
Iloperidone—Vertigo—Prednisolone—psoriasis	0.000203	0.000695	CcSEcCtD
Iloperidone—Oedema—Cyclosporine—psoriasis	0.000203	0.000694	CcSEcCtD
Iloperidone—Eye disorder—Betamethasone—psoriasis	0.000202	0.000693	CcSEcCtD
Iloperidone—Eye disorder—Dexamethasone—psoriasis	0.000202	0.000693	CcSEcCtD
Iloperidone—Dry mouth—Mycophenolate mofetil—psoriasis	0.000202	0.00069	CcSEcCtD
Iloperidone—Infection—Cyclosporine—psoriasis	0.000201	0.000689	CcSEcCtD
Iloperidone—Confusional state—Mycophenolate mofetil—psoriasis	0.000199	0.000682	CcSEcCtD
Iloperidone—Nervous system disorder—Cyclosporine—psoriasis	0.000199	0.00068	CcSEcCtD
Iloperidone—Vertigo—Hydrocortisone—psoriasis	0.000198	0.000679	CcSEcCtD
Iloperidone—Body temperature increased—Mycophenolic acid—psoriasis	0.000198	0.000678	CcSEcCtD
Iloperidone—Dizziness—Hydroxyurea—psoriasis	0.000198	0.000677	CcSEcCtD
Iloperidone—Oedema—Mycophenolate mofetil—psoriasis	0.000198	0.000677	CcSEcCtD
Iloperidone—Asthma—Methotrexate—psoriasis	0.000197	0.000674	CcSEcCtD
Iloperidone—Angiopathy—Betamethasone—psoriasis	0.000197	0.000672	CcSEcCtD
Iloperidone—Angiopathy—Dexamethasone—psoriasis	0.000197	0.000672	CcSEcCtD
Iloperidone—Infection—Mycophenolate mofetil—psoriasis	0.000196	0.000672	CcSEcCtD
Iloperidone—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000194	0.000663	CcSEcCtD
Iloperidone—Arrhythmia—Dexamethasone—psoriasis	0.000193	0.000662	CcSEcCtD
Iloperidone—Arrhythmia—Betamethasone—psoriasis	0.000193	0.000662	CcSEcCtD
Iloperidone—Tachycardia—Mycophenolate mofetil—psoriasis	0.000193	0.00066	CcSEcCtD
Iloperidone—Abdominal discomfort—Methotrexate—psoriasis	0.000189	0.000646	CcSEcCtD
Iloperidone—Rash—Hydroxyurea—psoriasis	0.000189	0.000645	CcSEcCtD
Iloperidone—Dermatitis—Hydroxyurea—psoriasis	0.000188	0.000645	CcSEcCtD
Iloperidone—Myalgia—Hydrocortisone—psoriasis	0.000188	0.000643	CcSEcCtD
Iloperidone—Vertigo—Triamcinolone—psoriasis	0.000187	0.000639	CcSEcCtD
Iloperidone—Connective tissue disorder—Prednisone—psoriasis	0.000185	0.000634	CcSEcCtD
Iloperidone—Hypotension—Mycophenolate mofetil—psoriasis	0.000185	0.000632	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000185	0.000632	CcSEcCtD
Iloperidone—Oedema—Prednisolone—psoriasis	0.000184	0.000631	CcSEcCtD
Iloperidone—Dysuria—Methotrexate—psoriasis	0.000184	0.00063	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Methotrexate—psoriasis	0.000183	0.000626	CcSEcCtD
Iloperidone—Paraesthesia—Cyclosporine—psoriasis	0.000182	0.000623	CcSEcCtD
Iloperidone—Erectile dysfunction—Methotrexate—psoriasis	0.000181	0.000621	CcSEcCtD
Iloperidone—Dyspnoea—Cyclosporine—psoriasis	0.000181	0.000618	CcSEcCtD
Iloperidone—Somnolence—Cyclosporine—psoriasis	0.00018	0.000617	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.00018	0.000616	CcSEcCtD
Iloperidone—Oedema—Hydrocortisone—psoriasis	0.00018	0.000616	CcSEcCtD
Iloperidone—Tachycardia—Prednisolone—psoriasis	0.00018	0.000616	CcSEcCtD
Iloperidone—Asthenia—Mycophenolic acid—psoriasis	0.00018	0.000615	CcSEcCtD
Iloperidone—Infection—Hydrocortisone—psoriasis	0.000179	0.000612	CcSEcCtD
Iloperidone—Nausea—Hydroxyurea—psoriasis	0.000178	0.000608	CcSEcCtD
Iloperidone—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000178	0.000608	CcSEcCtD
Iloperidone—Myalgia—Triamcinolone—psoriasis	0.000177	0.000605	CcSEcCtD
Iloperidone—Nervous system disorder—Hydrocortisone—psoriasis	0.000177	0.000604	CcSEcCtD
Iloperidone—Eye disorder—Prednisone—psoriasis	0.000176	0.000603	CcSEcCtD
Iloperidone—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000176	0.000603	CcSEcCtD
Iloperidone—Tachycardia—Hydrocortisone—psoriasis	0.000176	0.000602	CcSEcCtD
Iloperidone—Somnolence—Mycophenolate mofetil—psoriasis	0.000176	0.000601	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000175	0.000599	CcSEcCtD
Iloperidone—Fatigue—Cyclosporine—psoriasis	0.000175	0.000598	CcSEcCtD
Iloperidone—Dry mouth—Triamcinolone—psoriasis	0.000173	0.000592	CcSEcCtD
Iloperidone—Diarrhoea—Mycophenolic acid—psoriasis	0.000171	0.000587	CcSEcCtD
Iloperidone—Stomatitis—Methotrexate—psoriasis	0.000171	0.000586	CcSEcCtD
Iloperidone—Angiopathy—Prednisone—psoriasis	0.000171	0.000586	CcSEcCtD
Iloperidone—Conjunctivitis—Methotrexate—psoriasis	0.000171	0.000584	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000171	0.000584	CcSEcCtD
Iloperidone—Oedema—Triamcinolone—psoriasis	0.00017	0.00058	CcSEcCtD
Iloperidone—Vertigo—Betamethasone—psoriasis	0.000169	0.00058	CcSEcCtD
Iloperidone—Vertigo—Dexamethasone—psoriasis	0.000169	0.00058	CcSEcCtD
Iloperidone—Arrhythmia—Prednisone—psoriasis	0.000168	0.000577	CcSEcCtD
Iloperidone—Infection—Triamcinolone—psoriasis	0.000168	0.000577	CcSEcCtD
Iloperidone—Hypotension—Hydrocortisone—psoriasis	0.000168	0.000576	CcSEcCtD
Iloperidone—Feeling abnormal—Cyclosporine—psoriasis	0.000167	0.000572	CcSEcCtD
Iloperidone—Hepatobiliary disease—Methotrexate—psoriasis	0.000166	0.000568	CcSEcCtD
Iloperidone—Dizziness—Mycophenolic acid—psoriasis	0.000166	0.000567	CcSEcCtD
Iloperidone—Epistaxis—Methotrexate—psoriasis	0.000166	0.000567	CcSEcCtD
Iloperidone—Paraesthesia—Prednisolone—psoriasis	0.000166	0.000567	CcSEcCtD
Iloperidone—Tachycardia—Triamcinolone—psoriasis	0.000166	0.000566	CcSEcCtD
Iloperidone—Mental disorder—Prednisone—psoriasis	0.000165	0.000566	CcSEcCtD
Iloperidone—Malnutrition—Prednisone—psoriasis	0.000164	0.000562	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000164	0.000562	CcSEcCtD
Iloperidone—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000163	0.000558	CcSEcCtD
Iloperidone—Paraesthesia—Hydrocortisone—psoriasis	0.000162	0.000553	CcSEcCtD
Iloperidone—Myalgia—Betamethasone—psoriasis	0.000161	0.000549	CcSEcCtD
Iloperidone—Myalgia—Dexamethasone—psoriasis	0.000161	0.000549	CcSEcCtD
Iloperidone—Body temperature increased—Cyclosporine—psoriasis	0.00016	0.000548	CcSEcCtD
Iloperidone—Rash—Mycophenolic acid—psoriasis	0.000158	0.000541	CcSEcCtD
Iloperidone—Dermatitis—Mycophenolic acid—psoriasis	0.000158	0.00054	CcSEcCtD
Iloperidone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000156	0.000535	CcSEcCtD
Iloperidone—Urinary tract disorder—Methotrexate—psoriasis	0.000156	0.000533	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000155	0.000532	CcSEcCtD
Iloperidone—Fatigue—Hydrocortisone—psoriasis	0.000155	0.000531	CcSEcCtD
Iloperidone—Vision blurred—Prednisone—psoriasis	0.000155	0.00053	CcSEcCtD
Iloperidone—Urethral disorder—Methotrexate—psoriasis	0.000155	0.000529	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000155	0.000529	CcSEcCtD
Iloperidone—Oedema—Betamethasone—psoriasis	0.000154	0.000527	CcSEcCtD
Iloperidone—Oedema—Dexamethasone—psoriasis	0.000154	0.000527	CcSEcCtD
Iloperidone—Infection—Dexamethasone—psoriasis	0.000153	0.000523	CcSEcCtD
Iloperidone—Infection—Betamethasone—psoriasis	0.000153	0.000523	CcSEcCtD
Iloperidone—Paraesthesia—Triamcinolone—psoriasis	0.000152	0.000521	CcSEcCtD
Iloperidone—Feeling abnormal—Prednisolone—psoriasis	0.000152	0.00052	CcSEcCtD
Iloperidone—Anaemia—Prednisone—psoriasis	0.000152	0.000519	CcSEcCtD
Iloperidone—Dyspnoea—Triamcinolone—psoriasis	0.000151	0.000517	CcSEcCtD
Iloperidone—Nervous system disorder—Betamethasone—psoriasis	0.000151	0.000516	CcSEcCtD
Iloperidone—Nervous system disorder—Dexamethasone—psoriasis	0.000151	0.000516	CcSEcCtD
Iloperidone—Agitation—Prednisone—psoriasis	0.000151	0.000516	CcSEcCtD
Iloperidone—Tachycardia—Dexamethasone—psoriasis	0.00015	0.000514	CcSEcCtD
Iloperidone—Tachycardia—Betamethasone—psoriasis	0.00015	0.000514	CcSEcCtD
Iloperidone—Nausea—Mycophenolic acid—psoriasis	0.000149	0.000509	CcSEcCtD
Iloperidone—Feeling abnormal—Hydrocortisone—psoriasis	0.000148	0.000508	CcSEcCtD
Iloperidone—Vertigo—Prednisone—psoriasis	0.000148	0.000505	CcSEcCtD
Iloperidone—Eye disorder—Methotrexate—psoriasis	0.000147	0.000504	CcSEcCtD
Iloperidone—Tinnitus—Methotrexate—psoriasis	0.000147	0.000503	CcSEcCtD
Iloperidone—Cardiac disorder—Methotrexate—psoriasis	0.000146	0.000501	CcSEcCtD
Iloperidone—Fatigue—Triamcinolone—psoriasis	0.000146	0.0005	CcSEcCtD
Iloperidone—Asthenia—Cyclosporine—psoriasis	0.000145	0.000498	CcSEcCtD
Iloperidone—Hypotension—Dexamethasone—psoriasis	0.000144	0.000492	CcSEcCtD
Iloperidone—Hypotension—Betamethasone—psoriasis	0.000144	0.000492	CcSEcCtD
Iloperidone—Angiopathy—Methotrexate—psoriasis	0.000143	0.000489	CcSEcCtD
Iloperidone—Body temperature increased—Hydrocortisone—psoriasis	0.000142	0.000487	CcSEcCtD
Iloperidone—Mediastinal disorder—Methotrexate—psoriasis	0.000142	0.000486	CcSEcCtD
Iloperidone—Asthenia—Mycophenolate mofetil—psoriasis	0.000142	0.000485	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00014	0.00048	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00014	0.00048	CcSEcCtD
Iloperidone—Arthralgia—Prednisone—psoriasis	0.00014	0.000478	CcSEcCtD
Iloperidone—Myalgia—Prednisone—psoriasis	0.00014	0.000478	CcSEcCtD
Iloperidone—Feeling abnormal—Triamcinolone—psoriasis	0.00014	0.000478	CcSEcCtD
Iloperidone—Diarrhoea—Cyclosporine—psoriasis	0.000139	0.000475	CcSEcCtD
Iloperidone—Paraesthesia—Dexamethasone—psoriasis	0.000138	0.000473	CcSEcCtD
Iloperidone—Paraesthesia—Betamethasone—psoriasis	0.000138	0.000473	CcSEcCtD
Iloperidone—Mental disorder—Methotrexate—psoriasis	0.000138	0.000473	CcSEcCtD
Iloperidone—Malnutrition—Methotrexate—psoriasis	0.000137	0.00047	CcSEcCtD
Iloperidone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000135	0.000463	CcSEcCtD
Iloperidone—Body temperature increased—Triamcinolone—psoriasis	0.000134	0.000459	CcSEcCtD
Iloperidone—Dizziness—Cyclosporine—psoriasis	0.000134	0.000459	CcSEcCtD
Iloperidone—Oedema—Prednisone—psoriasis	0.000134	0.000459	CcSEcCtD
Iloperidone—Infection—Prednisone—psoriasis	0.000133	0.000456	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000133	0.000455	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Betamethasone—psoriasis	0.000133	0.000455	CcSEcCtD
Iloperidone—Fatigue—Betamethasone—psoriasis	0.000133	0.000454	CcSEcCtD
Iloperidone—Fatigue—Dexamethasone—psoriasis	0.000133	0.000454	CcSEcCtD
Iloperidone—Nervous system disorder—Prednisone—psoriasis	0.000131	0.00045	CcSEcCtD
Iloperidone—Tachycardia—Prednisone—psoriasis	0.000131	0.000448	CcSEcCtD
Iloperidone—Dizziness—Mycophenolate mofetil—psoriasis	0.000131	0.000447	CcSEcCtD
Iloperidone—Vision blurred—Methotrexate—psoriasis	0.000129	0.000443	CcSEcCtD
Iloperidone—Asthenia—Hydrocortisone—psoriasis	0.000129	0.000442	CcSEcCtD
Iloperidone—Rash—Cyclosporine—psoriasis	0.000128	0.000437	CcSEcCtD
Iloperidone—Dermatitis—Cyclosporine—psoriasis	0.000128	0.000437	CcSEcCtD
Iloperidone—Anaemia—Methotrexate—psoriasis	0.000127	0.000434	CcSEcCtD
Iloperidone—Feeling abnormal—Dexamethasone—psoriasis	0.000127	0.000434	CcSEcCtD
Iloperidone—Feeling abnormal—Betamethasone—psoriasis	0.000127	0.000434	CcSEcCtD
Iloperidone—Rash—Mycophenolate mofetil—psoriasis	0.000125	0.000427	CcSEcCtD
Iloperidone—Dermatitis—Mycophenolate mofetil—psoriasis	0.000125	0.000426	CcSEcCtD
Iloperidone—Vertigo—Methotrexate—psoriasis	0.000123	0.000422	CcSEcCtD
Iloperidone—Diarrhoea—Hydrocortisone—psoriasis	0.000123	0.000422	CcSEcCtD
Iloperidone—Leukopenia—Methotrexate—psoriasis	0.000123	0.00042	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Prednisone—psoriasis	0.000122	0.000418	CcSEcCtD
Iloperidone—Dizziness—Prednisolone—psoriasis	0.000122	0.000417	CcSEcCtD
Iloperidone—Asthenia—Triamcinolone—psoriasis	0.000122	0.000416	CcSEcCtD
Iloperidone—Body temperature increased—Betamethasone—psoriasis	0.000122	0.000416	CcSEcCtD
Iloperidone—Body temperature increased—Dexamethasone—psoriasis	0.000122	0.000416	CcSEcCtD
Iloperidone—Nausea—Cyclosporine—psoriasis	0.00012	0.000412	CcSEcCtD
Iloperidone—Paraesthesia—Prednisone—psoriasis	0.00012	0.000412	CcSEcCtD
Iloperidone—Dizziness—Hydrocortisone—psoriasis	0.000119	0.000408	CcSEcCtD
Iloperidone—Nausea—Mycophenolate mofetil—psoriasis	0.000117	0.000402	CcSEcCtD
Iloperidone—Myalgia—Methotrexate—psoriasis	0.000117	0.0004	CcSEcCtD
Iloperidone—Arthralgia—Methotrexate—psoriasis	0.000117	0.0004	CcSEcCtD
Iloperidone—Rash—Prednisolone—psoriasis	0.000116	0.000398	CcSEcCtD
Iloperidone—Dermatitis—Prednisolone—psoriasis	0.000116	0.000398	CcSEcCtD
Iloperidone—Fatigue—Prednisone—psoriasis	0.000116	0.000395	CcSEcCtD
Iloperidone—Rash—Hydrocortisone—psoriasis	0.000114	0.000389	CcSEcCtD
Iloperidone—Dermatitis—Hydrocortisone—psoriasis	0.000113	0.000388	CcSEcCtD
Iloperidone—Confusional state—Methotrexate—psoriasis	0.000113	0.000386	CcSEcCtD
Iloperidone—Dizziness—Triamcinolone—psoriasis	0.000112	0.000384	CcSEcCtD
Iloperidone—Infection—Methotrexate—psoriasis	0.000111	0.000381	CcSEcCtD
Iloperidone—Feeling abnormal—Prednisone—psoriasis	0.00011	0.000378	CcSEcCtD
Iloperidone—Asthenia—Betamethasone—psoriasis	0.00011	0.000378	CcSEcCtD
Iloperidone—Asthenia—Dexamethasone—psoriasis	0.00011	0.000378	CcSEcCtD
Iloperidone—Nervous system disorder—Methotrexate—psoriasis	0.00011	0.000376	CcSEcCtD
Iloperidone—Nausea—Prednisolone—psoriasis	0.00011	0.000375	CcSEcCtD
Iloperidone—Nausea—Hydrocortisone—psoriasis	0.000107	0.000366	CcSEcCtD
Iloperidone—Rash—Triamcinolone—psoriasis	0.000107	0.000366	CcSEcCtD
Iloperidone—Dermatitis—Triamcinolone—psoriasis	0.000107	0.000366	CcSEcCtD
Iloperidone—Body temperature increased—Prednisone—psoriasis	0.000106	0.000363	CcSEcCtD
Iloperidone—Diarrhoea—Dexamethasone—psoriasis	0.000105	0.00036	CcSEcCtD
Iloperidone—Diarrhoea—Betamethasone—psoriasis	0.000105	0.00036	CcSEcCtD
Iloperidone—Hypotension—Methotrexate—psoriasis	0.000105	0.000358	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000102	0.000349	CcSEcCtD
Iloperidone—Dizziness—Dexamethasone—psoriasis	0.000102	0.000348	CcSEcCtD
Iloperidone—Dizziness—Betamethasone—psoriasis	0.000102	0.000348	CcSEcCtD
Iloperidone—Nausea—Triamcinolone—psoriasis	0.000101	0.000345	CcSEcCtD
Iloperidone—Paraesthesia—Methotrexate—psoriasis	0.000101	0.000344	CcSEcCtD
Iloperidone—Dyspnoea—Methotrexate—psoriasis	9.98e-05	0.000342	CcSEcCtD
Iloperidone—Somnolence—Methotrexate—psoriasis	9.96e-05	0.000341	CcSEcCtD
Iloperidone—Rash—Betamethasone—psoriasis	9.7e-05	0.000332	CcSEcCtD
Iloperidone—Rash—Dexamethasone—psoriasis	9.7e-05	0.000332	CcSEcCtD
Iloperidone—Dermatitis—Dexamethasone—psoriasis	9.69e-05	0.000332	CcSEcCtD
Iloperidone—Dermatitis—Betamethasone—psoriasis	9.69e-05	0.000332	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Methotrexate—psoriasis	9.67e-05	0.000331	CcSEcCtD
Iloperidone—Fatigue—Methotrexate—psoriasis	9.66e-05	0.00033	CcSEcCtD
Iloperidone—Asthenia—Prednisone—psoriasis	9.61e-05	0.000329	CcSEcCtD
Iloperidone—Feeling abnormal—Methotrexate—psoriasis	9.23e-05	0.000316	CcSEcCtD
Iloperidone—Diarrhoea—Prednisone—psoriasis	9.17e-05	0.000314	CcSEcCtD
Iloperidone—Nausea—Betamethasone—psoriasis	9.14e-05	0.000313	CcSEcCtD
Iloperidone—Nausea—Dexamethasone—psoriasis	9.14e-05	0.000313	CcSEcCtD
Iloperidone—Dizziness—Prednisone—psoriasis	8.86e-05	0.000303	CcSEcCtD
Iloperidone—Body temperature increased—Methotrexate—psoriasis	8.85e-05	0.000303	CcSEcCtD
Iloperidone—Rash—Prednisone—psoriasis	8.45e-05	0.000289	CcSEcCtD
Iloperidone—Dermatitis—Prednisone—psoriasis	8.44e-05	0.000289	CcSEcCtD
Iloperidone—Asthenia—Methotrexate—psoriasis	8.04e-05	0.000275	CcSEcCtD
Iloperidone—Nausea—Prednisone—psoriasis	7.96e-05	0.000272	CcSEcCtD
Iloperidone—Diarrhoea—Methotrexate—psoriasis	7.66e-05	0.000262	CcSEcCtD
Iloperidone—Dizziness—Methotrexate—psoriasis	7.41e-05	0.000253	CcSEcCtD
Iloperidone—Rash—Methotrexate—psoriasis	7.06e-05	0.000242	CcSEcCtD
Iloperidone—Dermatitis—Methotrexate—psoriasis	7.05e-05	0.000241	CcSEcCtD
Iloperidone—Nausea—Methotrexate—psoriasis	6.65e-05	0.000228	CcSEcCtD
Iloperidone—HTR6—GPCR downstream signaling—CXCL8—psoriasis	1.56e-05	0.000342	CbGpPWpGaD
Iloperidone—HTR7—GPCR downstream signaling—CXCL8—psoriasis	1.56e-05	0.000342	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—TYK2—psoriasis	1.56e-05	0.000341	CbGpPWpGaD
Iloperidone—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	1.55e-05	0.00034	CbGpPWpGaD
Iloperidone—DRD4—GPCR downstream signaling—CXCL8—psoriasis	1.49e-05	0.000327	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—SOCS1—psoriasis	1.47e-05	0.000322	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—SOCS1—psoriasis	1.45e-05	0.000318	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—VEGFA—psoriasis	1.44e-05	0.000315	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—CAT—psoriasis	1.43e-05	0.000314	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—CXCL8—psoriasis	1.42e-05	0.000311	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—CXCL8—psoriasis	1.42e-05	0.00031	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—CXCL8—psoriasis	1.41e-05	0.000308	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—TYK2—psoriasis	1.4e-05	0.000307	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—CAT—psoriasis	1.39e-05	0.000305	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—TYK2—psoriasis	1.38e-05	0.000303	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—CXCL8—psoriasis	1.35e-05	0.000297	CbGpPWpGaD
Iloperidone—DRD1—GPCR downstream signaling—CXCL8—psoriasis	1.34e-05	0.000295	CbGpPWpGaD
Iloperidone—DRD3—GPCR downstream signaling—CXCL8—psoriasis	1.32e-05	0.000291	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SOCS1—psoriasis	1.26e-05	0.000277	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—LEP—psoriasis	1.26e-05	0.000276	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—APOE—psoriasis	1.26e-05	0.000276	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—APOE—psoriasis	1.26e-05	0.000276	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—LEP—psoriasis	1.26e-05	0.000276	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SOCS1—psoriasis	1.26e-05	0.000276	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—APOE—psoriasis	1.25e-05	0.000274	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—LEP—psoriasis	1.25e-05	0.000274	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SOCS1—psoriasis	1.22e-05	0.000268	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—CXCL8—psoriasis	1.22e-05	0.000268	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—TYK2—psoriasis	1.2e-05	0.000264	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—LEP—psoriasis	1.2e-05	0.000264	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—APOE—psoriasis	1.2e-05	0.000264	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—CXCL8—psoriasis	1.2e-05	0.000264	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—TYK2—psoriasis	1.2e-05	0.000263	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CARM1—psoriasis	1.19e-05	0.000262	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—NFKBIA—psoriasis	1.17e-05	0.000257	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—NFKBIA—psoriasis	1.17e-05	0.000257	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—VEGFA—psoriasis	1.17e-05	0.000256	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—TYK2—psoriasis	1.17e-05	0.000256	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—NFKBIA—psoriasis	1.16e-05	0.000255	CbGpPWpGaD
Iloperidone—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	1.15e-05	0.000253	CbGpPWpGaD
Iloperidone—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	1.15e-05	0.000252	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—CAT—psoriasis	1.13e-05	0.000247	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—NFKBIA—psoriasis	1.12e-05	0.000246	CbGpPWpGaD
Iloperidone—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	1.12e-05	0.000245	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—APOE—psoriasis	1.11e-05	0.000244	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SOCS1—psoriasis	1.11e-05	0.000243	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SOCS1—psoriasis	1.09e-05	0.000239	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SOCS1—psoriasis	1.09e-05	0.000239	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.09e-05	0.000238	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—TP53—psoriasis	1.09e-05	0.000238	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—LEP—psoriasis	1.08e-05	0.000238	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—APOE—psoriasis	1.08e-05	0.000238	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—APOE—psoriasis	1.08e-05	0.000237	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—APOE—psoriasis	1.07e-05	0.000235	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—LEP—psoriasis	1.07e-05	0.000235	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SOCS1—psoriasis	1.07e-05	0.000234	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—TYK2—psoriasis	1.06e-05	0.000232	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—CXCL8—psoriasis	1.05e-05	0.00023	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.04e-05	0.000229	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.000228	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.000228	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—CAT—psoriasis	1.04e-05	0.000227	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—CAT—psoriasis	1.03e-05	0.000227	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—TYK2—psoriasis	1.02e-05	0.000224	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	1.01e-05	0.000223	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1.01e-05	0.000222	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CARM1—psoriasis	1.01e-05	0.000222	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—NFKBIA—psoriasis	1.01e-05	0.000222	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	9.98e-06	0.000219	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—NFKBIA—psoriasis	9.97e-06	0.000219	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—CXCL8—psoriasis	9.95e-06	0.000218	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SOCS1—psoriasis	9.93e-06	0.000218	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	9.77e-06	0.000214	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PPARG—psoriasis	9.67e-06	0.000212	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TYK2—psoriasis	9.61e-06	0.000211	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TYK2—psoriasis	9.6e-06	0.000211	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TYK2—psoriasis	9.54e-06	0.000209	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—TYK2—psoriasis	9.47e-06	0.000208	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.46e-06	0.000208	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PPARG—psoriasis	9.4e-06	0.000206	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—LEP—psoriasis	9.32e-06	0.000205	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—APOE—psoriasis	9.32e-06	0.000205	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—LEP—psoriasis	9.27e-06	0.000203	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—APOE—psoriasis	9.27e-06	0.000203	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—CXCL8—psoriasis	9.21e-06	0.000202	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TYK2—psoriasis	9.19e-06	0.000202	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	9.08e-06	0.000199	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—CXCL8—psoriasis	9.06e-06	0.000199	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—CXCL8—psoriasis	9.04e-06	0.000198	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—APOE—psoriasis	9.02e-06	0.000198	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—LEP—psoriasis	9.02e-06	0.000198	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	8.87e-06	0.000195	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—TP53—psoriasis	8.81e-06	0.000193	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—APOE—psoriasis	8.76e-06	0.000192	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NFKBIA—psoriasis	8.69e-06	0.000191	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NFKBIA—psoriasis	8.64e-06	0.00019	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	8.41e-06	0.000184	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—CXCL8—psoriasis	8.37e-06	0.000184	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—CXCL8—psoriasis	8.36e-06	0.000183	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—CXCL8—psoriasis	8.3e-06	0.000182	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TYK2—psoriasis	8.27e-06	0.000182	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	8.24e-06	0.000181	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—LEP—psoriasis	8.18e-06	0.00018	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—APOE—psoriasis	8.18e-06	0.00018	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TYK2—psoriasis	8.16e-06	0.000179	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—LEP—psoriasis	8.05e-06	0.000177	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—APOE—psoriasis	8.05e-06	0.000177	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—APOE—psoriasis	8.05e-06	0.000177	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—LEP—psoriasis	8.04e-06	0.000176	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—APOE—psoriasis	8.04e-06	0.000176	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—APOE—psoriasis	8.03e-06	0.000176	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—CXCL8—psoriasis	8e-06	0.000176	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—IL6—psoriasis	7.96e-06	0.000175	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—IL6—psoriasis	7.95e-06	0.000174	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—IL6—psoriasis	7.9e-06	0.000173	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—LEP—psoriasis	7.89e-06	0.000173	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—APOE—psoriasis	7.89e-06	0.000173	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CARM1—psoriasis	7.81e-06	0.000171	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—JUN—psoriasis	7.78e-06	0.000171	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—JUN—psoriasis	7.77e-06	0.000171	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—JUN—psoriasis	7.72e-06	0.000169	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PPARG—psoriasis	7.63e-06	0.000167	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NFKBIA—psoriasis	7.63e-06	0.000167	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—IL6—psoriasis	7.61e-06	0.000167	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NFKBIA—psoriasis	7.5e-06	0.000165	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—NFKB1—psoriasis	7.49e-06	0.000164	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NFKBIA—psoriasis	7.49e-06	0.000164	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—NFKB1—psoriasis	7.48e-06	0.000164	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—JUN—psoriasis	7.44e-06	0.000163	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—NFKB1—psoriasis	7.43e-06	0.000163	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CAT—psoriasis	7.35e-06	0.000161	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	7.35e-06	0.000161	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—LEP—psoriasis	7.33e-06	0.000161	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—APOE—psoriasis	7.33e-06	0.000161	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CXCL8—psoriasis	7.2e-06	0.000158	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—NFKB1—psoriasis	7.16e-06	0.000157	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TYK2—psoriasis	7.11e-06	0.000156	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CXCL8—psoriasis	7.11e-06	0.000156	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TYK2—psoriasis	7.08e-06	0.000155	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PPARG—psoriasis	7.01e-06	0.000154	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PPARG—psoriasis	6.99e-06	0.000153	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TYK2—psoriasis	6.88e-06	0.000151	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—IL6—psoriasis	6.85e-06	0.00015	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	6.83e-06	0.00015	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—VEGFA—psoriasis	6.8e-06	0.000149	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—VEGFA—psoriasis	6.79e-06	0.000149	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—IL6—psoriasis	6.76e-06	0.000148	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—VEGFA—psoriasis	6.74e-06	0.000148	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—STAT3—psoriasis	6.73e-06	0.000148	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—STAT3—psoriasis	6.72e-06	0.000147	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—JUN—psoriasis	6.7e-06	0.000147	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—STAT3—psoriasis	6.68e-06	0.000147	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—JUN—psoriasis	6.61e-06	0.000145	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—VEGFA—psoriasis	6.5e-06	0.000143	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—NFKB1—psoriasis	6.45e-06	0.000141	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—STAT3—psoriasis	6.44e-06	0.000141	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—NFKB1—psoriasis	6.36e-06	0.00014	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TYK2—psoriasis	6.25e-06	0.000137	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CAT—psoriasis	6.22e-06	0.000137	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CXCL8—psoriasis	6.19e-06	0.000136	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CXCL8—psoriasis	6.16e-06	0.000135	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TYK2—psoriasis	6.15e-06	0.000135	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TYK2—psoriasis	6.13e-06	0.000135	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TYK2—psoriasis	6.02e-06	0.000132	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CXCL8—psoriasis	5.99e-06	0.000132	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—IL6—psoriasis	5.89e-06	0.000129	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—IL6—psoriasis	5.86e-06	0.000129	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—VEGFA—psoriasis	5.85e-06	0.000128	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—STAT3—psoriasis	5.79e-06	0.000127	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—VEGFA—psoriasis	5.77e-06	0.000127	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—JUN—psoriasis	5.76e-06	0.000126	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—JUN—psoriasis	5.73e-06	0.000126	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—STAT3—psoriasis	5.72e-06	0.000125	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—APOE—psoriasis	5.71e-06	0.000125	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—IL6—psoriasis	5.7e-06	0.000125	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TYK2—psoriasis	5.59e-06	0.000123	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—JUN—psoriasis	5.57e-06	0.000122	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NFKB1—psoriasis	5.54e-06	0.000122	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NFKB1—psoriasis	5.51e-06	0.000121	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CXCL8—psoriasis	5.44e-06	0.000119	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NFKB1—psoriasis	5.36e-06	0.000118	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CXCL8—psoriasis	5.35e-06	0.000117	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CXCL8—psoriasis	5.34e-06	0.000117	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CXCL8—psoriasis	5.24e-06	0.000115	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL6—psoriasis	5.17e-06	0.000113	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—psoriasis	5.14e-06	0.000113	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—psoriasis	5.13e-06	0.000113	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—psoriasis	5.1e-06	0.000112	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—psoriasis	5.09e-06	0.000112	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—psoriasis	5.08e-06	0.000111	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—JUN—psoriasis	5.06e-06	0.000111	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—psoriasis	5.03e-06	0.00011	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—psoriasis	5.01e-06	0.00011	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—psoriasis	4.98e-06	0.000109	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—psoriasis	4.98e-06	0.000109	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—JUN—psoriasis	4.98e-06	0.000109	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PPARG—psoriasis	4.97e-06	0.000109	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—JUN—psoriasis	4.96e-06	0.000109	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—psoriasis	4.96e-06	0.000109	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—psoriasis	4.91e-06	0.000108	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—JUN—psoriasis	4.87e-06	0.000107	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CXCL8—psoriasis	4.87e-06	0.000107	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—psoriasis	4.87e-06	0.000107	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NFKB1—psoriasis	4.87e-06	0.000107	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—APOE—psoriasis	4.84e-06	0.000106	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—psoriasis	4.82e-06	0.000106	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CAT—psoriasis	4.8e-06	0.000105	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NFKB1—psoriasis	4.79e-06	0.000105	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NFKB1—psoriasis	4.78e-06	0.000105	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—psoriasis	4.7e-06	0.000103	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—psoriasis	4.7e-06	0.000103	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NFKB1—psoriasis	4.69e-06	0.000103	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—psoriasis	4.66e-06	0.000102	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—psoriasis	4.63e-06	0.000102	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—JUN—psoriasis	4.53e-06	9.93e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—psoriasis	4.49e-06	9.86e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—psoriasis	4.42e-06	9.7e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—psoriasis	4.42e-06	9.69e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—psoriasis	4.37e-06	9.6e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—psoriasis	4.36e-06	9.57e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NFKB1—psoriasis	4.36e-06	9.56e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—psoriasis	4.35e-06	9.54e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—psoriasis	4.34e-06	9.52e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—psoriasis	4.3e-06	9.44e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—psoriasis	4.29e-06	9.42e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—psoriasis	4.26e-06	9.34e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—psoriasis	4.21e-06	9.25e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PPARG—psoriasis	4.21e-06	9.24e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—psoriasis	4.05e-06	8.88e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—psoriasis	3.99e-06	8.76e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—psoriasis	3.95e-06	8.68e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—psoriasis	3.92e-06	8.59e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—psoriasis	3.8e-06	8.34e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—psoriasis	3.78e-06	8.3e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—APOE—psoriasis	3.73e-06	8.19e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—psoriasis	3.68e-06	8.07e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—psoriasis	3.48e-06	7.63e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—psoriasis	3.46e-06	7.6e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—psoriasis	3.37e-06	7.39e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—psoriasis	3.34e-06	7.32e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—psoriasis	3.28e-06	7.21e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—psoriasis	3.28e-06	7.19e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPARG—psoriasis	3.25e-06	7.13e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—psoriasis	3.22e-06	7.06e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—psoriasis	3.06e-06	6.7e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—psoriasis	3.01e-06	6.6e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—psoriasis	3e-06	6.58e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—psoriasis	2.99e-06	6.56e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—psoriasis	2.94e-06	6.46e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—psoriasis	2.73e-06	6e-05	CbGpPWpGaD
